Business Context and Reporting Period
Company: Aprea Therapeutics, Inc. (APRE)
Filing Type: Form 8-K (Current Report)
Date of Report: March 16, 2026
Reporting Period: The filing announces financial results for the three and twelve months ended December 31, 2025, and provides an operational update for the same period.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. It references a press release (Exhibit 99.1) containing the actual figures. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not detail specific material changes in financial performance or operations compared to prior periods. It only confirms that an update on operations was issued alongside the financial results.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release and updated its corporate presentation slide deck (Exhibit 99.2) to provide an operational update. Specific guidance or outlook details are contained within these exhibits and are not present in the main filing text.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text. The filing includes a standard disclaimer that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the period ended December 31, 2025.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines, pipeline progress, and forward-looking guidance.
- Verify the Company's cash runway and burn rate, as these are critical for a pre-revenue biotechnology firm but are not listed in the cover sheet.
- Confirm any new regulatory milestones or partnership announcements referenced in the operational update.